<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553108</url>
  </required_header>
  <id_info>
    <org_study_id>D0816C00024</org_study_id>
    <nct_id>NCT03553108</nct_id>
  </id_info>
  <brief_title>A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.</brief_title>
  <acronym>IVIVC</acronym>
  <official_title>A Phase 1, Randomised, Open-label, 4-Period Crossover Study to Develop an In Vitro-In Vivo Correlation for Olaparib Tablets in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 open label, 4 treatment, 4 sequence and 4 period crossover study in&#xD;
      subjects with solid tumours no longer responding to, or eligible for standard therapies, and&#xD;
      for whom there are no additional standard therapies likely to benefit the subject.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open-label, randomised, 4-period, 4-sequence crossover pharmacokinetic study&#xD;
      designed to generate in vivo PK data from tablet variants with different size/geometry and&#xD;
      dose, to correlate with their corresponding in vitro dissolution profiles. The duration of&#xD;
      each dosing period is 7 days including the washout period. Subjects will be randomised to a&#xD;
      treatment sequence, following a balanced Latin Squares design. Twelve subjects who meet&#xD;
      inclusion/exclusion criteria and have provided informed consent will be randomly assigned to&#xD;
      the treatment sequences: ABCD, BDAC, CADB, or DCBA.&#xD;
&#xD;
      On Day 1 of each period, subjects will receive a single dose of either Treatment A, B, C, or&#xD;
      D, according to the randomisation schedule. Serial blood samples for determination of&#xD;
      olaparib in plasma will be collected for up to 72 hours.&#xD;
&#xD;
      Cancer subjects with advanced solid tumours are required for this study, as pre-clinical&#xD;
      toxicology data preclude the use of olaparib in healthy volunteers. The olaparib doses chosen&#xD;
      will deliver exposure at or below that which has been previously demonstrated to be&#xD;
      acceptable and tolerated in cancer subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2018</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Protocol designed to evaluate one or more interventions for treating a disease, syndrome or condition</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>%PECmax</measure>
    <time_frame>0 to 72 hours</time_frame>
    <description>Percent prediction error for Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>%PEAUC</measure>
    <time_frame>0 to 72 hours</time_frame>
    <description>Percent prediction error for AUC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) obtained directly from the observed concentration versus time data.</measure>
    <time_frame>Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles.</time_frame>
    <description>Evaluation of the PK parameters for the different Olaparib tablet variants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (tmax) obtained directly from the observed concentration versus time data.</measure>
    <time_frame>Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles.</time_frame>
    <description>Evaluation of the PK parameters for the different Olaparib tablet variants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to the time of the last measurable concentration (AUC(0-t)) calculated by linear up/log down trapezoidal summation.</measure>
    <time_frame>Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles.</time_frame>
    <description>Evaluation of the PK parameters for the different Olaparib tablet variants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve from zero (pre-dose) extrapolated to infinity (AUC)</measure>
    <time_frame>Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles.</time_frame>
    <description>Evaluation of the PK parameters for the different Olaparib tablet variants. calculated by linear up/log down trapezoidal summation and extrapolated to infinity by addition of the last quantifiable concentration divided by the terminal rate constant: AUC(0-t) + Clast/λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent plasma clearance (CL/F).</measure>
    <time_frame>Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles.</time_frame>
    <description>Evaluation of the PK parameters for the different Olaparib tablet variants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t½). Visual assessment will be used to identify the terminal linear phase of the concentration-time profile.</measure>
    <time_frame>Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles.</time_frame>
    <description>Evaluation of the PK parameters for the different Olaparib tablet variants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F).</measure>
    <time_frame>Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles.</time_frame>
    <description>Evaluation of the PK parameters for the different Olaparib tablet variants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant (λz) estimated by log-linear least squares regression of the terminal part of the concentration-time curve.</measure>
    <time_frame>Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles.</time_frame>
    <description>Evaluation of the PK parameters for the different Olaparib tablet variants.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Malignant Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Olaparib Treatment Sequence ABCD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.&#xD;
A - Olaparib Tablet 25 mg B - Olaparib Tablet 100 mg C - Olaparib Tablet 150 mg D - Olaparib Tablet 250 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaparib Treatment Sequence BDAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.&#xD;
B - Olaparib Tablet 100 mg D - Olaparib Tablet 250 mg A - Olaparib Tablet 25 mg C - Olaparib Tablet 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaparib Treatment Sequence CADB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.&#xD;
C - Olaparib Tablet 150 mg A - Olaparib Tablet 25 mg D - Olaparib Tablet 250 mg B - Olaparib Tablet 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaparib Treatment Sequence DCBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.&#xD;
D - Olaparib Tablet 250 mg C - Olaparib Tablet 150 mg B - Olaparib Tablet 100 mg A - Olaparib Tablet 25 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib Treatment A</intervention_name>
    <description>Olaparib Tablet 25 mg</description>
    <arm_group_label>Olaparib Treatment Sequence ABCD</arm_group_label>
    <arm_group_label>Olaparib Treatment Sequence BDAC</arm_group_label>
    <arm_group_label>Olaparib Treatment Sequence CADB</arm_group_label>
    <arm_group_label>Olaparib Treatment Sequence DCBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib Treatment B</intervention_name>
    <description>Olaparib Tablet 100 mg</description>
    <arm_group_label>Olaparib Treatment Sequence ABCD</arm_group_label>
    <arm_group_label>Olaparib Treatment Sequence BDAC</arm_group_label>
    <arm_group_label>Olaparib Treatment Sequence CADB</arm_group_label>
    <arm_group_label>Olaparib Treatment Sequence DCBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib Treatment C</intervention_name>
    <description>Olaparib Tablet 150 mg</description>
    <arm_group_label>Olaparib Treatment Sequence ABCD</arm_group_label>
    <arm_group_label>Olaparib Treatment Sequence BDAC</arm_group_label>
    <arm_group_label>Olaparib Treatment Sequence CADB</arm_group_label>
    <arm_group_label>Olaparib Treatment Sequence DCBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib Treatment D</intervention_name>
    <description>Olaparib Tablet 250 mg</description>
    <arm_group_label>Olaparib Treatment Sequence ABCD</arm_group_label>
    <arm_group_label>Olaparib Treatment Sequence BDAC</arm_group_label>
    <arm_group_label>Olaparib Treatment Sequence CADB</arm_group_label>
    <arm_group_label>Olaparib Treatment Sequence DCBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent prior to any study specific procedures.&#xD;
&#xD;
          2. Female or male subject, aged &gt; 18 years.&#xD;
&#xD;
          3. Histologically or, where appropriate, cytologically confirmed malignant solid tumour&#xD;
             refractory or resistant to standard therapy for which no suitable effective standard&#xD;
             therapy is available and in the opinion of the investigator might benefit from&#xD;
             olaparib therapy.&#xD;
&#xD;
          4. Subjects must have normal organ and bone marrow function measured within 28 days prior&#xD;
             to administration of study treatment as defined below:&#xD;
&#xD;
               -  Haemoglobin ≥ 100 g/L with no blood transfusion in the past 28 days.&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109/L.&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT))&#xD;
                  / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤&#xD;
                  2.5 x institutional upper limit of normal unless liver metastases are present in&#xD;
                  which case they must be ≤ 5x ULN.&#xD;
&#xD;
               -  Subjects must have creatinine clearance estimated of ≥51 mL/min using the&#xD;
                  Cockcroft-Gault equation or based on a 24 hour urine test:&#xD;
&#xD;
             Estimated creatinine clearance =[(140-age [years]) x weight (kg) x 1.2] (x F)a serum&#xD;
             creatinine (μmol/L) a where F=0.85 for females and F=1 for males&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
          6. Subjects must have a life expectancy ≥ 16 weeks.&#xD;
&#xD;
          7. Postmenopausal or evidence of non-childbearing status for women of childbearing&#xD;
             potential: negative urine or serum pregnancy test within 28 days of study treatment&#xD;
             and confirmed prior to treatment on day 1.&#xD;
&#xD;
        8 Male subjects must use a condom during treatment and for 3 months after the last dose of&#xD;
        olaparib when having sexual intercourse with a pregnant woman or with a woman of&#xD;
        childbearing potential. Female partners of male subjects should also use a highly effective&#xD;
        form of contraception if they are of childbearing potential.&#xD;
&#xD;
        9 Subjects must have normal GI tract anatomy and function (see exclusion criteria for&#xD;
        specifics).&#xD;
&#xD;
        10 Subjects is willing and able to comply with the protocol for the duration of the study&#xD;
        including undergoing treatment and scheduled visits and examinations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca&#xD;
             staff and/or staff at the study site).&#xD;
&#xD;
          2. Previous randomisation in the present study.&#xD;
&#xD;
          3. Participation in another clinical study with an investigational product during the&#xD;
             last 1 month.&#xD;
&#xD;
          4. Any previous treatment with a PARP inhibitor, including olaparib.&#xD;
&#xD;
          5. Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as&#xD;
             judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic&#xD;
             arrhythmia, congestive heart failure, QTcF prolongation &gt; 500 ms, electrolyte&#xD;
             disturbances, etc.) or subjects with congenital long QT syndrome.&#xD;
&#xD;
          6. Subjects receiving any systemic chemotherapy or radiotherapy (except for palliative&#xD;
             reasons) within 3 weeks prior to study treatment.&#xD;
&#xD;
          7. Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin,&#xD;
             clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir,&#xD;
             saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g.&#xD;
             ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout&#xD;
             period prior to starting olaparib is 2 weeks.&#xD;
&#xD;
          8. Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin,&#xD;
             rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or&#xD;
             moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout&#xD;
             period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3&#xD;
             weeks for other agents.&#xD;
&#xD;
          9. Persistent toxicities (Common Terminology Criteria for Adverse Event (CTCAE) &gt; grade&#xD;
             2) caused by previous cancer therapy, excluding alopecia.&#xD;
&#xD;
         10. Subjects with myelodysplastic syndrome/acute myeloid leukaemia or with features&#xD;
             suggestive of MDS/AML.&#xD;
&#xD;
         11. Subjects with symptomatic uncontrolled brain metastases. A scan to confirm the absence&#xD;
             of brain metastases is not required. The subject can receive a stable dose of&#xD;
             corticosteroids before and during the study as long as these were started at least 4&#xD;
             weeks prior to treatment. Subjects with spinal cord compression unless considered to&#xD;
             have received definitive treatment for this and evidence of clinically stable disease&#xD;
             for 28 days&#xD;
&#xD;
         12. Major surgery within 2 weeks of starting study treatment and subjects must have&#xD;
             recovered from any effects of any major surgery.&#xD;
&#xD;
         13. Subjects considered a poor medical risk due to a serious, uncontrolled medical&#xD;
             disorder, non-malignant systemic disease or active, uncontrolled infection. Examples&#xD;
             include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3&#xD;
             months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal&#xD;
             cord compression, superior vena cava syndrome, extensive interstitial bilateral lung&#xD;
             disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder&#xD;
             that prohibits obtaining informed consent.&#xD;
&#xD;
         14. Subjects unable to swallow orally administered medication and subjects with&#xD;
             gastrointestinal disorders likely to interfere with absorption of the study medication&#xD;
             including surgery on the upper GI tract and small bowel, malabsorptive disorders,&#xD;
             inflammatory bowel disease, GI motility disorders, chronic diarrhea (more than 3 loose&#xD;
             bowel movements per day) chronic constipation (no bowel movement for more than two&#xD;
             days), recent (in last week) vomiting.&#xD;
&#xD;
         15. Pregnant or breastfeeding women.&#xD;
&#xD;
         16. Immunocompromised subjects, e.g., subjects who are known to be serologically positive&#xD;
             for human immunodeficiency virus (HIV).&#xD;
&#xD;
         17. Subjects with a known hypersensitivity to olaparib or any of the excipients of the&#xD;
             product.&#xD;
&#xD;
         18. Subjects with known active hepatitis (i.e. Hepatitis B or C) due to risk of&#xD;
             transmitting the infection through blood or other body fluids.&#xD;
&#xD;
         19. Previous allogenic bone marrow transplant or double umbilical cord blood&#xD;
             transplantation (dUCBT).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Punie</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Aiekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luc Dirix</last_name>
    <role>Principal Investigator</role>
    <affiliation>GZA Ziekenhuizen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guy Jerusalem</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Liege</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study team has decided that IPD would not be shared at this moment.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

